ID   MB49
AC   CVCL_7076
SY   MB-49
DR   BTO; BTO:0003562
DR   AddexBio; C0002004/5005
DR   CancerTools; 153368
DR   Millipore; SCC148
DR   Ubigene; YC-C104
DR   Wikidata; Q54904112
DR   Ximbio; 153368
RX   PubMed=107359;
RX   PubMed=19539312;
RX   PubMed=22559978;
RX   PubMed=29732388;
RX   PubMed=29784854;
RX   PubMed=30867744;
CC   Karyotypic information: Has lost chromosome Y (PubMed=22559978).
CC   Transformant: ChEBI; CHEBI:59032; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
CC   Breed/subspecies: C57BL/ICRF-a(t).
ST   Source(s): Millipore; Ubigene
ST   Mouse STR 1-1: 15,16
ST   Mouse STR 1-2: 19
ST   Mouse STR 11-2: 16
ST   Mouse STR 12-1: 17
ST   Mouse STR 13-1: 17
ST   Mouse STR 15-3: 22.3
ST   Mouse STR 17-2: 14,15
ST   Mouse STR 18-3: 16
ST   Mouse STR 19-2: 14
ST   Mouse STR 2-1: 16
ST   Mouse STR 3-2: 13,14
ST   Mouse STR 4-2: 20.3
ST   Mouse STR 5-5: 17
ST   Mouse STR 6-4: 18
ST   Mouse STR 6-7: 15
ST   Mouse STR 7-1: 26.2
ST   Mouse STR 8-1: 16
ST   Mouse STR X-1: 28 (Ubigene)
ST   Mouse STR X-1: 28,29 (Millipore)
DI   NCIt; C25823; Mouse bladder transitional cell carcinoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 16
//
RX   PubMed=107359; DOI=10.1093/jnci/62.4.1017;
RA   Summerhayes I.C., Franks L.M.;
RT   "Effects of donor age on neoplastic transformation of adult mouse
RT   bladder epithelium in vitro.";
RL   J. Natl. Cancer Inst. 62:1017-1023(1979).
//
RX   PubMed=19539312; DOI=10.1016/j.juro.2009.03.076;
RA   Lodillinsky C., Rodriguez V., Vauthay L., Sandes E., Casabe A.,
RA   Eijan A.M.;
RT   "Novel invasive orthotopic bladder cancer model with high cathepsin B
RT   activity resembling human bladder cancer.";
RL   J. Urol. 182:749-755(2009).
//
RX   PubMed=22559978; DOI=10.1016/j.cancergen.2012.02.002;
RA   Fabris V.T., Lodillinsky C., Pampena M.B., Belgorosky D., Lanari C.,
RA   Eijan A.M.;
RT   "Cytogenetic characterization of the murine bladder cancer model MB49
RT   and the derived invasive line MB49-I.";
RL   Cancer Genet. 205:168-176(2012).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=29784854; DOI=10.1158/0008-5472.CAN-18-0173;
RA   Saito R., Smith C.C., Utsumi T., Bixby L.M., Kardos J., Wobker S.E.,
RA   Stewart K.G., Chai S.-J., Manocha U., Byrd K.M., Damrauer J.S.,
RA   Williams S.E., Vincent B.G., Kim W.Y.;
RT   "Molecular subtype-specific immunocompetent models of high-grade
RT   urothelial carcinoma reveal differential neoantigen expression and
RT   response to immunotherapy.";
RL   Cancer Res. 78:3954-3968(2018).
//
RX   PubMed=30867744; DOI=10.3892/ol.2019.9995;
RA   Alberto M., Cuello H.A., Gulino C.A., Pifano M., Belgorosky D.,
RA   Gabri M.R., Eijan A.M., Segatori V.I.;
RT   "Expression of bladder cancer-associated glycans in murine tumor cell
RT   lines.";
RL   Oncol. Lett. 17:3141-3150(2019).
//